Archived News Releases

Archived News Releases

Keyword Search

Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference

11/24/20
Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

11/18/20
Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020

11/11/20
Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference

11/10/20
Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update

10/29/20
Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain

10/21/20
Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020

10/20/20
Pacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020

10/07/20
Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

09/18/20
IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs

09/15/20
Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference

09/11/20
Pacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020

09/09/20
Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update

08/06/20
Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

08/05/20
Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

08/05/20
Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

08/04/20
Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020

07/30/20
Pacira BioSciences Announces Settlement of Government Investigation

07/28/20
Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025

07/07/20
Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes

07/06/20
Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020

07/06/20
Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes

07/02/20
Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference

06/16/20
Pacira BioSciences to Present at the 2020 Jefferies Virtual Healthcare Conference

05/27/20
Pacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

05/13/20
Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update

05/07/20
Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer

05/04/20
Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020

04/30/20
Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference

03/09/20
Pacira Reports Record Fourth Quarter and Full-Year Revenues

02/20/20
Pacira to Report 2019 Financial Results on Thursday February 20, 2020

02/13/20
Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services

01/21/20
Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

01/09/20
Pacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

01/08/20
EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients

01/07/20